» Articles » PMID: 20179295

Obesity, Endogenous Hormone Metabolism, and Prostate Cancer Risk: a Conundrum of "highs" and "lows"

Overview
Specialty Oncology
Date 2010 Feb 25
PMID 20179295
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

This perspective on the report by Neuhouser et al. (beginning on page 279 in this issue of the journal) examines the associations that have been observed between body mass index, serum insulin, preexisting diabetes, androgen metabolism, and prostate cancer risk. Based on data of the Prostate Cancer Prevention Trial, the observations by Neuhouser et al. plus findings from other studies suggest a complex mix of higher and lower risks for high- and low-grade cancer in association with obesity and endogenous hormone metabolism.

Citing Articles

Adiposity assessed close to diagnosis and prostate cancer prognosis in the EPIC study.

Cariolou M, Christakoudi S, Gunter M, Key T, Perez-Cornago A, Travis R JNCI Cancer Spectr. 2024; 8(5).

PMID: 39180334 PMC: 11410200. DOI: 10.1093/jncics/pkae070.


Pilot Study on the Locoregional Demographics of Prostate Cancer in River State, Nigeria.

Raphael J, Danagogo O Niger Med J. 2024; 62(6):340-345.

PMID: 38736520 PMC: 11087682. DOI: 10.60787/NMJ-62-6-65.


Underlying Features of Prostate Cancer-Statistics, Risk Factors, and Emerging Methods for Its Diagnosis.

Berenguer C, Pereira F, Camara J, Pereira J Curr Oncol. 2023; 30(2):2300-2321.

PMID: 36826139 PMC: 9955741. DOI: 10.3390/curroncol30020178.


Investigating the Role of Obesity in Prostate Cancer and Identifying Biomarkers for Drug Discovery: Systems Biology and Deep Learning Approaches.

Yeh S, Chung Y, Chen B Molecules. 2022; 27(3).

PMID: 35164166 PMC: 8840188. DOI: 10.3390/molecules27030900.


Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial.

Chau C, Till C, Price D, Goodman P, Neuhouser M, Pollak M Endocr Relat Cancer. 2021; 29(2):99-109.

PMID: 34889205 PMC: 8776589. DOI: 10.1530/ERC-21-0107.